ASweetLife Team
Amylin Lilly Logo

Type 2 Diabetes Drug Byetta Recommended as Add-on Therapy to Insulin

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the European Union (EU) for the expanded use of Byetta (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone)...
0 Shares
Cellnovo

Cellnovo Launches World’s First Mobile-Connected Insulin Pump

British based Cellnovo announced the commercial launch of the its new mobile-connected diabetes management system, and the start of the largest usability trial ever to investigate insulin pump technology for patients with type 1 diabetes. The trial will also be the first in which all clinical data is captured remotely, in real-time, using the mobile data connectivity of the Cellnovo system...
0 Shares

5 Low Carb Chocolate Valentine’s Day Desserts

We rarely eat anything sweet, and we don't usually publish recipes with sweeteners of any sort. But sometimes you have to make exceptions. Valentine's Day is one of those times. If you're going to celebrate Valentine's Day with chocolate, there are ways to do it that shouldn't make your blood sugar soar.
0 Shares
merck logo

FDA Approves Merck’s New Type 2 Diabetes Drug Janumet

The FDA has approved Merck's (MSD) new type 2 diabetes medication, JANUMET(R) XR (sitagliptin and metformin hydrochloride (HCl) extended-release) The new treatment combines sitagliptin, which is the active component of Januvia (sitagliptin), with extended-release metformin...
0 Shares
Lilly - Boehringer - logo

FDA Approves New Type 2 Diabetes Combination Medication Jentadueto

The FDA has approved Eli Lilly and Boehringer Ingelheim's new type 2 diabetes treatment Jentadueto (linagliptin/metformin hydrochloride), which combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet...
0 Shares
Amylin logo

FDA Approves Type 2 Diabetes Drug Bydureon

Amylin Pharmaceuticals, Inc. and Alkermes plc received FDA approval for Bydureon, a next generation once-weekly treatment for type 2 diabetes. The drug which received EU approval in June was turned down by the FDA twice during 2010, requesting further testing be conducted...
0 Shares